Ropinirole in the treatment of restless legs syndrome

Expert Review of Neurotherapeutics

Volumn 5, Issue 1, 2005, Pages 35-42

  Kakar, Rajdeep S ^a   Kushida, Clete A ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Dopamine agonist; Parkinson's disease; Periodic leg movements; Restless legs syndrome; Ropinirole; Sleep

Indexed keywords

GABAPENTIN; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FIRST PASS EFFECT; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; NAUSEA; NOSE CONGESTION; RESTLESS LEGS SYNDROME; SOMNOLENCE; STEADY STATE;

DOPAMINE AGONISTS; ENZYME INHIBITORS; EXPERT TESTIMONY; HUMANS; INDOLES; LEVODOPA; RESTLESS LEGS SYNDROME;

EID: 12344318106     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.1.35     Document Type: Article

References (68)

1. Allen RP, Hening WA, Montplaisir J et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from The RLS Diagnosis and Epidemiology workshop at the National Institute of Health. Sleep Med. 4(2), 101-119 (2003). Reviews the important considerations in confirming a diagnosis of restless legs syndrome (RLS).
2. Atlas Task Force of the American Sleep Disorders Association. Recording and scoring of leg movements. Sleep 16, 748-759 (1993).
3. Montplaisir J, Boucher S, Poirier G, Lazigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov. Disord. 12, 61-65 (1997).
4. Ferini-Strambi L, Bonati MT, Oldani A, Aridon P, Zucconi M, Casari G. Genetics in restless legs syndrome. Sleep Med. 5(3), 301-304 (2004).
5. Trenkwalder C, Paulus W. Why do restless legs occur at rest? Pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin. Neurophysiol. 115, 1975-1988 (2004). Second part of a current update on the pathophysiology of RLS.
6. Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov. Disord. 15, 154-158 (2000).
7. Michaud M, Dumont M, Selmaoui B, Paquet J, Fantini ML, Montplaisir J. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann. Neurol. 55(3), 372-380 (2004). Proposes the role of a circadian factor in the development of RLS.
8. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 52(5), 932-937 (1999).
9. Ruottinen HM, Partinen M, Hublin C et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 54(2), 502-504 (2000).
10. Eisensehr I, Wetter TC, Linke R et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 57(7), 1307-1309 (2001).
11. Earley CJ, Hyland K, Allen RP. CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. Mov. Disord. 16(1), 144-149 (2001).
12. Stiasny-Kolster K, Möller JC, Zschocke J et al. Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Mov. Disord. 19(2), 192-196 (2004).
13. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 21(4), 371-377 (1998).
14. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 54(8), 1698-1700 (2000).
15. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 56(2), 263-265 (2001).
16. Connor JR, Boyer PJ, Menzies SL et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 61(3), 304-309 (2003).
17. Earley CJ, Allen RP, Beard JL, Connor JR. Insight into the pathophysiology of restless legs syndrome. J. Neurosci. Res. 62(5), 623-628 (2000).
18. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch. Intern. Med. 160(14), 2137-2141 (2000).
19. The International Restless Legs Syndrome Study Group. The International Restless Legs Syndrome Study Group rating scale for Restless Legs Syndrome. Sleep Med. 4(2), 121-132 (2002). Explains the use of the Idiopathic Restless Legs Syndrome Rating Scale and its validation for the evaluation of RLS.
20. Ulfberg J, Nystrom B, Carter N, Edling C. Restless legs syndrome among working-aged women. Eur. Neurol. 46(1), 17-19 (2001).
21. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov. Disord. 16(6), 1159-1163 (2001).
22. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and morbidity in Augsberg elderly. Neurology 54(5), 1064-1068 (2000).
23. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 5(3), 237-246 (2004).
24. Kageyama T, Kabuto M, Nitta H et al. Prevalences of periodic limb movement-like and restless legs-like symptoms among Japanese adults. Psychiatry Clin. Neurosci. 54(3), 296-298 (2000).
25. Tan EK, Seah A, See SJ, Lim E, Wong MC, Koh KK. Restless legs syndrome in an Asian population: a study in Singapore. Mov. Disord. 16(3), 729-732 (2001).
26. Picchietti DL, Walters AS. Moderate to severe periodic limb movement disorder in childhood and adolescence. Sleep 22(3), 297-300 (1999).
27. Chervin RD, Archbold KH, Dillon JE et al. Associations between symptoms of inattention, hyperactivity, restless legs, and periodic limb movements. Sleep 25(2), 213-218 (2002). Examines the connections between RLS and attention deficit hyperactivity disorder and the comorbid effects on sleep and daytime function.
28. Michaud M, Paquet J, Lavigne G, Desautels A, Montplaisir J. Sleep laboratory diagnosis of restless legs syndrome. Eur. Neurol. 48(2), 108-113 (2002).
29. Michaud M, Lavigne G, Desautels A, Poirier G, Montplaisir J. Effects of immobility on sensory and motor symptoms of restless legs syndrome. Mov. Disord. 17(1), 112-115 (2002).
30. Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. Sleep 22(7), 961-968 (1999). First comprehensive, evidence-based review of the literature for treatment options in the management of RLS and periodic leg movement disorder.
31. Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27(3), 557-559 (2004).
32. The Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27(3), 560-567 (2004). Updated information and practice parameters on dopaminergic therapy for RLS.
33. Stiasny K, Wetter TC, Winkelmann J et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 56(10), 1399-1402 (2001).
34. Wetter TC, Stiasny K, Winkelmann J et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 52(5), 944-950 (1999).
35. Trenkwalder C, Hundemer HP, Lledo A et al. Efficacy of pergolide in treatment of restless legs syndrome: The PEARLS study. Neurology 62(8), 1391-1397 (2004).
36. Danoff SK, Grasso ME, Terry PB, Flynn JA. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 120(1), 313-316 (2001).
37. Pritchett AM, Morrison JF, Edwards WD. Valvular heart disease in patients taking pergolide. Mayo Clin. Proc. 77(12), 1280-1286 (2002).
38. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52(5), 938-943 (1999).
39. Stiasny-Kolster K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome: an open label trial. Neuropsychobiology 50(1), 65-70 (2004).
40. Becker PM, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology 51(4), 1221-1223 (1998).
41. Lin SC, Kaplan J, Burger CD, Fredrickson PA. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin. Proc. 73(6), 497-500 (1998).
42. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur. J. Neurol. 7(1), 127-131 (2000).
43. Stiasny K, Moller JC, Oertel WH. Safety of pramipexole in patients with restless legs syndrome. Neurology 55(10), 1589-1590 (2000).
44. Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 48(2), 82-86 (2003).
45. Adler CH, Sethi KD, Hauser RA et al. Ropinirole for the treatment of early Parkinsons disease. Neurology 49(2), 393-399 (1997).
46. Brooks DJ, Abbott RJ, Lees AJ et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinsons disease. Clin. Neuropharmacol. 21(2), 101-107 (1998).
47. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin. Neuropharmacol. 19(3), 234-245 (1996).
48. Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 51(4), 1057-1062 (1998).
49. GlaxoSmithKline. Requip® Package Insert (2001).
50. Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am. J. Health Syst. Pharm. 56(3), 217-224 (1999).
51. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin. Pharmacokinet. 39(4), 243-254 (2000).
52. Pellecchia MT, Vitale C, Sabatini M et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin. Neuropharmacol. 27(4), 178-181 (2004).
53. Saletu B, Gruber G, Saletu M et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 41(4), 181-189 (2000).
54. Saletu M, Anderer P, Saletu B et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals, and respiratory variables. Neuropsychobiology 41(4), 190-199 (2000).
55. Estivill E, De la Fuente V. The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: polysomnography data. Revista De Neurologia 29(9), 805-807 (1999).
56. Ondo W. Ropinirole for restless legs syndrome. Mov. Disord. 14(1), 138-140 (1999).
57. Estivill E, De la Fuente V, Barraquer A, Cilveti R. Use of ropinirole as a treatment of 10 patients with restless legs syndrome. 14th European Congress on Sleep Research, Madrid, Spain, 9-12 September. J. Sleep Res. 7(2), 80 (1998).
58. Garvez-Jimenez N, Khan T. Ropinirole and restless legs syndrome. Mov. Disord. 14(5), 890-892 (1999).
59. Trenkwalder C, Garcia-Borreguero D, Montagna P et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo-controlled study in 10 European countries. J. Neurol. Neurosurg. Psychiatry 75, 92-97 (2004). Large, randomized, placebo-controlled study evaluating the effects of ropinirole on RLS using subjective outcome measures.
60. Adler CH, Hauser RA, Sethi K et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 62, 1405-1407 (2004).
61. Montplaisir J, Karrasch J, Haan J, Kruger AJ, Volc D. The impact of ropinirole treatment on RLS symptoms and health-related quality of life (HRQOL) in patients with RLS: Results of a multinational 36-week study. Sleep 27, A293 (2004).
62. Allen R, Becker PM, Bogan R et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27(5), 907-914 (2004). Large, randomized, placebo-controlled trial evaluating the effects of ropinirole on RLS using both objective and subjective outcome measures.
63. Physicians' Desk Reference (2004).
64. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52(9), 1908-1910 (1999).
65. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 57(8), 1392-1396 (2001).
66. Pal S, Bhattacharya KF, Apapito C, Chaudhuri KR. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease taking pramipexole, cabergoline and levodopa mono and combination therapy. J. Neurol. Transm. 108(1), 71-77 (2002).
67. Hobson DE, Lang AE, Martin WR et al. Excessive daytime sleepiness and sudden onset sleep in Parkinson's disease: a survey by Canadian Movement Disorders Group. JAMA 287(4), 455-463 (2002).
68. Rye DB, Bliwise DL, Dihenia B, Gureki P. Daytime sleepiness in Parkinson's disease. J. Sleep Res. 9(1), 63-69 (2000).